Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.

The Journal of clinical endocrinology and metabolism - 1 Sept 2016

Langsted Anne, Nordestgaard Børge G, Benn Marianne, Tybjærg-Hansen Anne, Kamstrup Pia R

Abstract excerpt

CONTEXT: Novel, low-density lipoprotein (LDL) cholesterol-lowering proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors also lower lipoprotein(a) levels, but the effect on aortic valve stenosis and myocardial infarction is unknown. OBJECTIVE: We tested the hypothesis that the PCSK9 R46L loss-of-function mutation is associated with lower levels of lipoprotein(a) and with reduced risk of aortic valve...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aortic Valve Stenosis
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol, LDL

Share to Follow-Up Studies

Share to Heterozygote

Share to Lipoprotein(a)

Share to Myocardial Infarction

Share to Proprotein Convertase 9

Source

Identifiers

PMID: 27218270
DOI: 10.1210/jc.2016-1206

Genes

PCSK9

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.PMID 27218270Read ↗

PCSK9 R46L, Lower LDL, and Cardiovascular Disease Risk in Familial HypercholesterolemiaSemantic proximity Read ↗

Genetic inhibition of <i>PCSK9</i> , atherogenic lipoprotein concentrations, and calcific aortic valve stenosisSemantic proximity Read ↗

Rare Genetic Variants in LDLR, APOB, and PCSK9 Are Associated With Aortic Stenosis.Semantic proximity Read ↗

Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy-Brief Report.Semantic proximity Read ↗

PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses.Semantic proximity Read ↗

New Loss-of-Function Mutations in PCSK9 Reduce Plasma LDL Cholesterol.Semantic proximity Read ↗

Protective lipid-lowering variants in healthy older individuals without coronary heart disease.Semantic proximity Read ↗

Loss-of-function mutation of PCSK9 as a protective factor in the clinical expression of familial hypercholesterolemiaSemantic proximity Read ↗

R46L polymorphism in the PCSK9 gene: Relationship to lipid levels, subclinical vascular disease, and erectile dysfunction.Semantic proximity Read ↗

Effect of protein convertase subtilisin/kexin type 9 (PCSK9) 46L gene polymorphism on LDL cholesterol concentration in a Polish adult population.Semantic proximity Read ↗

Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke.Semantic proximity Read ↗

The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.